Published in Mol Microbiol on November 01, 2004
Proteomic analysis of the secretome of Leishmania donovani. Genome Biol (2008) 1.54
Ly49h-deficient C57BL/6 mice: a new mouse cytomegalovirus-susceptible model remains resistant to unrelated pathogens controlled by the NK gene complex. J Immunol (2008) 1.33
Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun (2008) 1.13
Gene expression analysis of wild Leishmania major isolates: identification of genes preferentially expressed in amastigotes. Parasitol Res (2006) 0.79
Overexpression of a single Leishmania major gene enhances parasite infectivity in vivo and in vitro. Mol Microbiol (2010) 0.77
Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol (2004) 2.01
Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection. J Biol Chem (2003) 1.42
Determinants for the development of visceral leishmaniasis disease. PLoS Pathog (2013) 1.22
Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun (2003) 1.20
Control of alpha subunit of eukaryotic translation initiation factor 2 (eIF2 alpha) phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2 alpha-dependent gene expression and cell death. Mol Cell Biol (2004) 1.18
Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun (2008) 1.13
Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervix. J Infect Dis (2006) 1.07
Development of a genetic assay to distinguish between Leishmania viannia species on the basis of isoenzyme differences. Clin Infect Dis (2006) 1.06
Comparison of the effects of Leishmania major or Leishmania donovani infection on macrophage gene expression. Infect Immun (2007) 1.04
Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen. Diagn Microbiol Infect Dis (2002) 1.03
First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis (2009) 1.01
Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis (2007) 1.00
Intracellular eukaryotic parasites have a distinct unfolded protein response. PLoS One (2011) 0.98
Reducing visceral leishmaniasis by insecticide impregnation of bed-nets, Bangladesh. Emerg Infect Dis (2013) 0.97
Screening Leishmania donovani-specific genes required for visceral infection. Mol Microbiol (2010) 0.96
Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol (2012) 0.92
Analysis of the PDZ binding specificities of Influenza A virus NS1 proteins. Virol J (2011) 0.91
Localization and induction of the A2 virulence factor in Leishmania: evidence that A2 is a stress response protein. Mol Microbiol (2010) 0.91
A FRET-based real-time PCR assay to identify the main causal agents of New World tegumentary leishmaniasis. PLoS Negl Trop Dis (2013) 0.91
Involvement of the Leishmania donovani virulence factor A2 in protection against heat and oxidative stress. Exp Parasitol (2012) 0.90
The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detect Prev (2005) 0.89
Leishmania donovani zymodeme MON-37 isolated from an autochthonous visceral leishmaniasis patient in Sri Lanka. Pathog Glob Health (2012) 0.89
Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18. J Gen Virol (2004) 0.89
Identification and characterization of a protein-tyrosine phosphatase in Leishmania: Involvement in virulence. J Biol Chem (2006) 0.89
Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53. J Virol (2005) 0.88
Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis. Vaccine (2012) 0.88
A genomic-based approach combining in vivo selection in mice to identify a novel virulence gene in Leishmania. PLoS Negl Trop Dis (2008) 0.86
Cross-sectional study to assess risk factors for leishmaniasis in an endemic region in Sri Lanka. Am J Trop Med Hyg (2013) 0.85
Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. J Med Microbiol (2011) 0.84
Heterologous expression of a mammalian protein tyrosine phosphatase gene in Leishmania: effect on differentiation. Mol Microbiol (2003) 0.83
Expression of a Leishmaniadonovani nucleotide sugar transporter in Leishmaniamajor enhances survival in visceral organs. Exp Parasitol (2011) 0.82
Viral load of episomal and integrated forms of human papillomavirus type 33 in high-grade squamous intraepithelial lesions of the uterine cervix. Int J Cancer (2007) 0.80
Detection of iNOS gene expression in cutaneous leishmaniasis biopsy tissue. Mol Biochem Parasitol (2002) 0.80
Comparison of p53 and the PDZ domain containing protein MAGI-3 regulation by the E6 protein from high-risk human papillomaviruses. Virol J (2008) 0.79
Role of cytosolic glyceraldehyde-3-phosphate dehydrogenase in visceral organ infection by Leishmania donovani. Eukaryot Cell (2012) 0.78
Deletion of an ATP-binding cassette protein subfamily C transporter in Leishmania donovani results in increased virulence. Mol Biochem Parasitol (2012) 0.77
A2 and other visceralizing proteins of Leishmania: role in pathogenesis and application for vaccine development. Subcell Biochem (2014) 0.76
Screening Leishmania donovani complex-specific genes required for visceral disease. Methods Mol Biol (2015) 0.76
Adaptation of Leishmania donovani to cutaneous and visceral environments: in vivo selection and proteomic analysis. J Proteome Res (2015) 0.75